07:52:48 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2023-02-24 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-27 Kvartalsrapport 2022-Q1
2022-05-06 Ordinarie utdelning POLAR 0.00 SEK
2022-05-05 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-28 Kvartalsrapport 2021-Q1
2021-05-06 Ordinarie utdelning POLAR 0.00 SEK
2021-05-05 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning POLAR 0.00 SEK
2020-06-30 Årsstämma 2020
2020-05-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2020-02-14 Extra Bolagsstämma 2020
2019-10-23 Kvartalsrapport 2019-Q3
2019-07-24 Kvartalsrapport 2019-Q2
2019-05-07 Split POLAR 16:1
2019-04-26 Kvartalsrapport 2019-Q1
2019-03-19 Årsstämma 2019
2019-02-04 Ordinarie utdelning POLAR 0.00 SEK
2019-02-01 Bokslutskommuniké 2018


Polarcool är verksamma inom medicinteknik. Idag är bolaget inriktade mot att produkter och lösningar inriktade för skador inom sport och aktivitet. Störst fokus återfinns inom forskning och utveckling av produkter som används vid behandling av hjärnskador vid exempelvis boxning, rugby och amerikansk fotboll. Verksamhet innehas på global nivå, med störst närvaro inom den europeiska marknaden.
2022-09-15 08:31:00

The med-tec company PolarCool AB (publ) announces that it has received a timeline from Intertek for approval of the company's own quality management system (QMS), under the EU's new Medical Device Regulation (MDR).

In an ongoing process with the Notified Body (NB) Intertek, PolarCool has made important progress in obtaining approval for the company's own quality management system ISO 13485 within the new MDR regulations. Intertek has provided PolarCool with a timeline for the upcoming certification process, the first part of which will begin in this autumn. The final part, which is a stage 2 audit, is planned to take place during June 2023. This is the last step for PolarCool in obtaining its own MDR certificate.

Today, PolarCool's med-tech product PolarCap® System is certified through the current cooperation agreement with BrainCool AB, which means that the product is manufactured and sold under BrainCool's QMS for quality assurance. When PolarCool receives its own approval, the product will be transferred to the company's own QMS.

PolarCool CEO Erik Andersson comments:

-The fact that we have now received a slot, and a timeline from Intertek means that we have taken a big step closer to our long goal of having our own QMS. The new MDR regulations from the EU place a very heavy burden on the Notified Bodies that issue certificates, which has resulted in a long queue time to start the process.

-At the same time, the current cooperation agreement with BrainCool has given us the opportunity to use their QMS, allowing us to be able to market and sell our product in Europe.

PolarCool develops and markets the product PolarCap® which alleviates the effects of concussion. The primary users of PolarCap® include sports clubs, organizations, and facilities in contact sports such as ice hockey, rugby, and handball, but also other sports with an increased risk of concussion.